Home > Insider Trading > Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc. (ARWR)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
11 - 20
Next >>

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.

Keep Reading →

August 8th, 2023 - News Transcripts

15 Worst Performing Biotech Stocks in 2023

In this article, we discuss 15 worst performing biotech stocks in 2023.

Keep Reading →

August 8th, 2023 - Hedge Funds News Stock Analysis

Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?

Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.

Keep Reading →

May 10th, 2023 - Hedge Fund Investor Letters News

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.

Keep Reading →

May 4th, 2023 - News Transcripts

12 High Growth Healthcare Stocks to Buy

The healthcare sector proved its mettle in 2022.

Keep Reading →

February 26th, 2023 - Hedge Funds News

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. I will now hand the conference over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead.

Keep Reading →

February 8th, 2023 - News Transcripts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode.

Keep Reading →

December 15th, 2022 - News Transcripts

Baron Funds Sold Arrowhead Pharmaceuticals (ARWR) to Reallocate to Higher Conviction Ideas

Baron Funds, an asset management company, released its “Baron Global Advantage Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.

Keep Reading →

September 13th, 2022 - Hedge Fund Investor Letters News

Baron Funds: "We Retain Conviction in Arrowhead (ARWR)"

Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.

Keep Reading →

June 14th, 2022 - Hedge Fund Investor Letters News